Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria: * Male type II diabetes patients diagnosed for more than 5 years and aged between 35 and 65 years. * Subjects treated with metformin alone or metformin and one other oral anti-diabetic drug. * Subjects should have FPG in the range of 6.0 to 11.0 mmol/L at screening and HbA1c less than 10% (HbA1c value according to international DCCT standard). Exclusion Criteria: * History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease. * Renal dysfunction. * Use of insulin, glitazones, warfarin and amiodarone within 3 months before enrolment and use of potent CYP450 inhibitors, e.g., ketoconazole and macrolide antibiotics within 14 days before administration of IP.